GlaxoSmithKline and Human Genome Sciences have entered into a definitive agreement under which GSK will acquire HGS for approximately $3 billion in cash, and represents a premium of 99% to the HGS closing price of $7.17 per share on April 18, 2012. The boards of directors of both companies have approved the transaction. Through complete ownership of BENLYSTA, albiglutide and darapladib, GSK plans to simplify and optimize R&D, and commercial and manufacturing operations. GSK expects to achie...